Isotretinoin Treatment for Acne Vulgaris: A Five-Year Retrospective Analysis of Clinical and Biochemical Adverse Effects
Journal of Clinical Medicine · 14.09.2025 · 14 (18) · 6473
DOI: 10.3390/jcm14186473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.09.2025. Verfasst von Igor Jarosław Feszak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Sciences, Pomeranian University in Słupsk, 76-200 Słupsk, Poland. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Oral isotretinoin remains the most effective therapy for severe acne, but its exceptional efficacy is often accompanied by relatively frequent adverse effects. In this study, we quantified the frequency- and dose-related predictors of clinical and biochemical adverse effects during isotretinoin treatment in routine Polish practice.
Methods
The records of 370 patients (mean age: 28 ± 12 years) who began isotretinoin treatment between June 2020 and June 2025 were reviewed. The mean daily isotretinoin and cumulative isotretinoin doses were 23.4 ± 9.1 mg and 88.3 ± 31.5 mg/kg, respectively. The adverse events documented at two-monthly visits were correlated with age and dosing. Lipid, hepatic, thyroid and prolactin panels were compared with age- and sex-matched controls using χ2 statistics and odds ratios (ORs).
Results
Xerosis (70%), retinoid dermatitis (20%) and cheilitis (15.5%) predominated. Hand eczema rose with higher daily isotretinoin doses (ρ = 0.082; p = 0.037), whereas pruritus declined with greater cumulative isotretinoin exposure (ρ = −0.088; p = 0.037). Retinoid dermatitis was linked to a younger age (ρ = −0.080; p = 0.0286), whereas desquamation increased slightly with age (ρ = +0.083 p = 0.0228). Overall, dyslipidemia was twice as common as in the controls (OR: 2.06; 95% CI: 1.49–2.86; p-value:
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Health Sciences, Pomeranian University in Słupsk, 76-200 Słupsk, Poland.
- Department of Pediatrics, Pediatric Oncology, and Immunology, Pomeranian Medical University, 71-252 Szczecin, Poland.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland.
ORCID-Profile: Igor Jarosław Feszak, Sylwia Feszak, Piotr Kawczak
Zitieren
APA
Feszak, I. J., Brzeziński, P., Feszak, S., Kitowska, A., Waśkow, M., Kawczak, P., & Bączek, T. (2025). Isotretinoin Treatment for Acne Vulgaris: A Five-Year Retrospective Analysis of Clinical and Biochemical Adverse Effects. Journal of Clinical Medicine, 14(18), 6473. https://doi.org/10.3390/jcm14186473
Vancouver
Feszak IJ, Brzeziński P, Feszak S, Kitowska A, Waśkow M, Kawczak P, et al. Isotretinoin Treatment for Acne Vulgaris: A Five-Year Retrospective Analysis of Clinical and Biochemical Adverse Effects. Journal of Clinical Medicine. 2025;14(18):6473. doi:10.3390/jcm14186473
BibTeX
@article{Feszak2025,
author = {Feszak, Igor Jarosław and Brzeziński, Piotr and Feszak, Sylwia and Kitowska, Aleksandra and Waśkow, Monika and Kawczak, Piotr and Bączek, Tomasz},
title = {Isotretinoin Treatment for Acne Vulgaris: A Five-Year Retrospective Analysis of Clinical and Biochemical Adverse Effects},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {18},
pages = {6473},
doi = {10.3390/jcm14186473}
}
EUVIMED